Targeted inhibition of proteins modulating epigenetic changes is an increasingly important priority in 12 cancer therapeutics, and many small molecule inhibitors are currently being developed. In the case of 13 neuroblastoma (NB), a paediatric solid tumour with a paucity of intragenic mutations, epigenetic 14 deregulation may be especially important. In this study we validate the histone methyltransferase 15 G9a/EHMT2 as being associated with indicators of poor prognosis in NB. Immunological analysis of 16
relationship between G9a and MYCN. This pattern of sensitivity is also evident when using small 23 molecule inhibitors of G9a, UNC0638 and UNC0642. The increased efficacy of G9a inhibition in the 24 presence of MYCN-overexpression is also demonstrated in the SHEP-21N isogenic model with tet-25 regulatable MYCN. Finally, using RNA sequencing, we identify several potential tumour suppressor 26 genes that are reactivated by G9a Neuroblastoma (NB) is a biologically and clinically heterogeneous cancer arising from the 32 developing sympathetic nervous system. About 25% of NB patients have a very poor prognosis 33 clinical subtype characterized by amplification of the MYCN proto-oncogene (Brodeur et al. 1984; 34 Brodeur 2003 ; Maris et al. 2007 ). Change of function gene mutations are relatively scarce in NB, but 35 include the oncogene ALK, which is frequently mutated in familial NB and in up to 10% of sporadic 36 cases (Mossë et al. 2008 ). This has prompted the notion that epigenetic aberrations are likely to 37 contribute to NB pathogenesis. 38
Consistent with this hypothesis, evidence has accrued for the involvement of epigenetic modifiers, 39 including histone methyltransferases (HMTs) in NB tumorigenesis. For example, we previously 40 showed that knockdown of the HMTs EZH2, CARM1 or PRMT5 all decreased survival of NB cells 41 (Park et al. 2015) . High levels of the MYCN transcription factor leads to activation of 42 survival/growth genes, but also repression of genes necessary for terminal differentiation in the 43 sympathetic nervous system (Westermark et al. 2011; Gherardi et al. 2013 ). MYCN represses genes 44 driving differentiation and apoptosis by a variety of means, including recruitment of epigenetic 45 repressors, such as histone deacetylases (Iraci et al. 2011 ) and the Polycomb protein EZH2 (Corvetta 46 et al. 2013 ). EZH2 has been independently shown to repress tumour suppressor genes in 47 neuroblastoma, including CASZ1, RUNX3, NGFR and CLU (Wang et al. 2012) . CLU, encoding 48
Clusterin, has been characterized as a haploinsufficient tumour suppressor gene in NB (Chayka et al. 49 2009). The widespread involvement of HMTs in tumorigenesis has led to concerted pharmaceutical 50 interest in developing selective inhibitors for HMTs (Helin and Dhanak 2013) 51 Another HMT implicated in NB is G9a (or EHMT2/KMT1C), the primary function of which is to 52 mono-or di-methylate histone 3 lysine 9 (H3K9) (Tachibana et al. 2002; Shinkai and Tachibana 2011) . These methylation marks are related to transcriptional activation and repression respectively, 54 and G9a mediated gene silencing has been shown to be involved in regulating differentiation of 55 embryonic stem cells (Wen et al. 2009 ). Moreover, G9a has multiple non-histone targets such as p53 56 (Huang et al. 2010 ) and chromatin remodelers Reptin and Pontin (Lee et al. 2010 ; Lee et al. 2011 ). In 57 these cases, the post-translational methylation of proteins can either inactivate protein function, as in 58 the case of p53, or in the case of Reptin and Pontin can direct these proteins to different targets to 59 alter target gene expression. G9a can also act as a co-factor independent of its HMT activity by 60 binding to nuclear receptor coactivator GRIP1 and forming a scaffold complex which in turn can 61 activate downstream targets (Lee et al. 2006 ). G9a is known to be overexpressed in a variety of 62 cancers such as colorectal ), bladder (Cho et al. 2011 ) and hepatocellular (Kondo et 63 al. 2007 ) carcinomas suggesting it is an oncoprotein and therefore a viable therapeutic target for 64 small molecule inhibitors. The G9a inhibitor BIX-01294 was one of the first HMT inhibitors 65 discovered, displaying over 20-fold greater inhibition of G9a compared to the closely related HMT 66 GLP (EHMT1). This inhibitor also showed no activity against a panel of HMTs including PRMT1, 67 SUV39H1, SET7/9 and ESET, and was able to reduce demethylated H3K9 (H3K9me2) levels in 68 chromatin (Kubicek et al. 2007) . A second generation inhibitor UNC0638 is a potent and highly 69 selective probe for G9a and GLP (>500-fold selectivity over other histone methyltransferases) and a 70 high toxicity/function ratio of >100 (Vedadi et al. 2011 ). UNC0642 has improved pharmacokinetic 71
properties and is suitable for use in vivo (Liu et al. 2013 ). UNC0638 and UNC0642 act as 72 competitive substrate inhibitors, thus blocking the SET domain from acquiring methyl groups from 73 its S-adenosyl-methionine (SAM) cofactor. 74
Three previous studies have alluded to the possibility of G9a as a therapeutic target in NB. On the 75 basis of microarray database analysis, Lu et al proposed that G9a may be oncogenic in NB, and 76 further showed that G9a knockdown or BIX-01294 treatment led to apoptosis in three NB cell-lines 77 (Lu et al. 2013) . In contrast, two other studies suggested that G9a knockdown or BIX-01294 78 treatment could trigger autophagic cell death (Ding et al. 2013; Ke et al. 2014 Ke et al. , 2019 , and that G9a-79 mediated epigenetic activation of serine-glycine metabolism genes is critical in oncogenesis. Taken 80 together, these papers agree that inhibiting G9a may be beneficial for NB therapy, but the mode of 81 action is unclear. In addition, the greatly more selective second generation of G9a inhibitors such as 82 UNC0638 and UNC0642 have not been evaluated.
In this study, we comprehensively assess the association of G9a with key prognostic factors in NB, 84 specifically differentiation status and MYCN over-expression. We further evaluate UNC0638 and 85 UNC0642 as potential therapeutic agents for NB, and identify putative tumour suppressor genes that 86 are repressed by G9a in NB. Our data strongly suggest that G9a inhibition may be especially 87 beneficial for poor-prognosis NB driven by MYCN amplification. 88 
Materials and Methods

MTT cell viability assay 110
NB cells were seeded in 96 well plates and treated the next day in triplicate with a serial dilution of 111 UNC0638/0642. After 72 hours, we added 10μL of MTT (5 mg/mL) (Sigma), followed by 50μL of 112 SDS lysis buffer (10% SDS (w/v), 1/2500 (v/v) 37% HCl) after a further 3 hours. Following an 113 overnight incubation at 37ºC, the plates were read at 570 and 650 nm, using SpectraMax 190 plate 114 reader (Molecular Devices). 115
Protein Extraction and Western blot 116
Floating and attached cells were lysed in Radioimmunoprecipitation assay (RIPA) buffer. Protein 117 concentration was determined by using Micro BCA TM protein assay kit (Thermo Fisher).
Immunoblotting was performed as described previously (Park et al. 2015 
Cell cycle analysis 137
Propidium-iodide labelling and fluorescence activated cell sorting analysis to detect cell cycle phases 138 was performed as previously described (Park et al. 2015) . 139
Immunohistochemistry 140
Tissue microarrays (TMAs), containing 50 peripheral neuroblastic tumours were stained using 141 antibodies for EZH2 (NCL-L-EZH2, Novocastra) and G9a/EHMT2 (EPR4019(2), Abcam). 142
Immunohistochemistry was independently scored by two pathologists blinded to the specimens, and 143 a score of 1-4 was assigned based on proportion of positive cells (0, no staining; 1, sporadic staining 144 of individual cells; 2, <20% of cells stained; 3, 20% to 50% of cells stained; 4, >50% of cells 145 stained). All human tissues were acquired with appropriate local research ethics committee approval.
Immunohistochemistry was performed with a Leica Microsystem Bond III automated machine using 147 the Bond Polymer Refine Detection Kit (Ref DS9800) followed by Bond Dab Enhancer (AR9432). 148
The slides were dewaxed with Bond Dewax Solution (AR9222). Heat mediated antigen retrieval was 149 performed using Bond Epitope Retrieval Solution for 20 mins. 150
RNA-seq and bioinformatic analysis 151
LAN-1 cells were treated with 3µM BIX-01294 and DMSO vehicle as control for 72 hours and were 152 subsequently harvested. RNA was extracted by using miRNeasy Mini Kit (Qiagen), according to 153 manufacturer's instructions. Libraries were constructed and sequenced as previously described 154 Results 168
G9a expression correlates with poor prognosis and MYCN amplification in NB 169
We first assessed the expression of G9a/EHMT2 in an RNA-seq dataset of 498 primary NBs (the 170 SEQC dataset, GSE62564) (Su et al. 2014) using the R2: Genomics Analysis and Visualization 171 Platform (http://r2.amc.nl). Kaplan-Meier analysis of overall survival showed that high G9a/EHMT2 172 expression was significantly associated with poor survival, ( Figure 1A ). Moreover, G9a/EHMT2 has 173 a significantly increased expression in MYCN-amplified (MNA) NBs ( Figure 1B) . In order to assess 174 whether this relationship at the RNA level was also apparent at the protein level, we conducted 175 immunoblotting of G9a protein expression in NB cell lines with and without MNA, and confirmed 176 that increased G9a protein expression was apparent in MNA NB cell lines ( Figure 1C -D). We next 177 examined G9a protein expression in a tissue microarray of 50 primary neuroblastic tumours, in 178 parallel with EZH2, which is known to be involved in NB. Strikingly, expression of G9a and EZH2 179 was barely detectable in the more differentiated ganglioneuromas and ganglioneuroblastomas, 180 generally regarded as low risk tumours (Figure 2A neuroblasts, underlining the link between differentiation status and G9a expression. Scoring the 186 tumours for G9a and EZH2 expression according to the percentage of immunopositive cells revealed 187 that G9a and EZH2 scores were very highly correlated (R=0.76, p=1.45e-10, Figure 2F ), indicative 188 of a potential functional interplay between these HMTs. Unfortunately, MYCN status was available 189 for only a few tissue microarray samples, therefore not sufficient for statistical analysis. 190
Nevertheless, our expression analyses at the RNA and protein levels shows that G9a over-expression 191 is associated with poor prognosis NB and MYCN/EZH2 status. 192
Short interfering RNA mediated G9a depletion leads to apoptotic cell death in MNA 193 neuroblastoma cells 194
As there is increased expression of G9a in MNA neuroblastoma cell lines, we next evaluated the 195 effect of short interfering RNA (siRNA) mediated G9a depletion on three MNA cell lines and three 196 non-MNA cell lines. Quantification of adherent and floating cells following knockdown of G9a in MNA Kelly, LAN-1, and SK-N-BE(2)C showed a consistent increase in the percentage of dead cells 198 (p<0.05) and decrease in the number of live cells in the population ( Figure 3A) . In order to assess the 199 mode of reduced cell survival, immunoblotting was carried out with markers for apoptosis (cleaved 200 PARP and cleaved caspase 3) and autophagy (LC3B). In all three MNA lines, apoptotic cell death 201 was verified by the increase in apoptosis markers ( Figure 3A, lower panel) . In contrast, no increases 202 in LC3B were apparent, suggesting little or no effect on autophagy. Knockdown in the presence of 203 QVD, a caspase inhibitor, led to decreased floating cells after G9a knockdown, and, as expected, no 204 apoptotic markers (Supplementary Figure 1A G9a depletion led to a significant increase in the percentage of dead cells, whereas there was no 220 change in cells without MYCN induction ( Figure 4A ). As before, this was despite a significant 221 decrease in live cell count that occurred across both induced and non-induced MYCN S21N cells 222 ( Figure 4A ). This was further confirmed by the immunoblots showing that G9a depletion led to an 223 increase in apoptosis markers in the MYCN induced cells only ( Figure 4B) . These experiments 224 further emphasise the G9a dependency of MYCN-overexpressing NB cells. 225
MNA NB cell are more sensitive to G9a inhibitors UNC0638 and UNC0642 226
As our genetic interference analyses demonstrate that NB cells may be vulnerable to decreased G9a 227 activity, we treated a panel of 13 NB cell lines and 2 two disease-free control cell lines with G9a 228 SMIs and conducted cell survival assays. Whilst all NB cell lines exhibited reduced viability upon 229 treatment with UNC0638 ( Figure 5A ) and UNC0642 ( Figure 5B ) in a concentration dependent 230 manner, there was no effect on the disease-free lines RPE-1 and NF-TERT. Importantly, consistent 231 with our genetic interference data, a clear pattern of greater sensitivity of MNA lines was observed. 232
For UNC0638, the average IC 50 was 8.3μM for MNA lines, compared to 19μM for non-MNA lines 233 (p<0.01). Similarly, for UNC0642 the average IC 50 s were 15μM and 32μM for MNA and non-MNA 234 lines respectively ( Figure 5C-F) . 235
Next, UNC0638 and UNC0642 were evaluated in S21N cells to further assess the association of 236 MYCN over-expression and sensitivity to pharmaceutical G9a inhibition. S21N cells with induced 237 (high) MYCN were more sensitive to G9ai by UNC0638 and UNC0642 than the uninduced cells 238 ( Figure 5G-H) . As with the cell-line panel, UNC0638 was slightly more potent than UNC0642, with 239 the IC 50 values for MYCN induced cells being 5.7μM and 10.6μM respectively, compared to 16.6μM 240 and 23.2μM for uninduced S21N cells ( Figure 5I ). All the IC 50 values for the cell-lines analysed are 241 detailed in Table 1 . Thus, our pharmaceutical inhibition assays reflect our genetic interference data, 242
showing that NB cell-lines are sensitive to both UNC0638 and UNC0642, with MYCN over-243 expressing cells being significantly more sensitive than non-MNA lines. 244
UNC0638 leads to increased apoptosis specifically in MNA NB lines 245
G9a knockdown analyses demonstrated that only MNA NB lines underwent programmed cell death, 246 despite all lines showing some degree of growth inhibition. To determine if the effects on cell death 247 and proliferation following G9a drug inhibition are akin to the results following G9a depletion as 248 shown in Figure 3 , three MNA and three non-MNA NB cell lines were treated with UNC0638 and 249 cell growth effects quantified, together with an assessment of apoptosis and autophagy markers. The 250 three most sensitive three MNA lines, Kelly, IMR-32 and LAN-1 all showed a significant increase in 251 the percentage of dead cells following treatment ( Figure 6A ). Apoptosis was verified by 252 immunoblotting, all 3 treated lines showing an increase in cleaved PARP and caspase 3 ( Figure 6A , 253 lower panel). Although Kelly and LAN-1 cells showed some increase in LC3B, IMR-32 cells 254 exhibited a decrease of LC3B. As with knockdowns, all 3 MNA lines showed a decrease in MYCN 255 protein.
Conversely, in the three non-MNA lines, SH-EP, GI-M-EN, and SH-SY5Y, there was no significant 257 change in the percentage dead cells. However, there was a significant decrease in the number of live 258 cells counted following the treatments ( Figure 6B ). There was no change in the apoptotic markers 259 after UNC0638 treatment; however, there was an increase in the autophagy marker LC3B in all three 260 non-MNA cell-lines. Together these experiments mirror the G9a depletion experiments with respect 261 to increased apoptosis and efficacy in MNA cell-lines. 262 Using the S21N model, we further evaluated the requirement for MYCN over-expression in 263 apoptosis triggered by UNC0638. Although there was no increase in the percentage of dead cells 264 without MYCN induction, a significant 2-fold increase in dead cells was apparent in the presence of 265 MYCN induction ( Figure 7A ). Immunoblotting showed that the autophagy marker LC3B was 266 increased following UNC0638 treatment regardless of MYCN levels. The apoptosis markers, 267 however, were only increased by UNC0638 in the presence of MYCN over-expression, further 268 confirming the requirement for G9a activity for the survival of MYCN over-expressing cells (Figure  269 7B). This further supports G9a activity for targeted therapeutics in NB, especially for patients with 270 MYCN amplification. 271
Identification of genes regulated by G9a inhibition in NB 272
We next sought insight into gene expression changes in MNA NB cells following G9a inhibition. For 273 this, we treated LAN-1 cells with BIX-01294, as this inhibitor would facilitate comparison with 274 previous studies on G9a in NB, including one attributing drug activity to changes in the expression of 275 genes involved in serine metabolism. Using RNA sequencing, we identified 115 genes whose 276 expression level was altered by more than 1.3-fold, at p<0.005. Consistent with the role of G9a in 277 epigenetic repression, the majority of these genes were upregulated after BIX-01294 treatment, but 278 approximately a third of affected genes were down-regulated ( Figure 8A ). The magnitude of gene 279 induction was generally much higher than the changes in down-regulated genes, with 11 genes being 280 upregulated between 10-100-fold more than vehicle treated cells. In contrast, down-regulated genes 281 were decreased by a maximum of approximately 5-fold. We have not detected changes in the genes 282 of the serine-glycine pathway as previously described (Ding et al. 2013 ) which may be due to 283 differences in culture conditions, namely supplementation with non-essential amino acids. A full list 284 of genes showing altered expression is given in Supplementary Table 2 . Gene set enrichment analysis 285 (GSEA) verified a profound effect on gene sets driven by the MYC family; in particular the MYCN-286 affected. MYCN induced genes from this data set were downregulated by BIX-01294, whereas 288 MYCN repressed genes were upregulated ( Figure 8B ). GSEA also showed that apoptosis gene sets 289 were upregulated, together with gene sets including genes epigenetically silenced by EZH2 and 290 histone deacetylases 1 and 3 (HDAC1 and HDAC3) ( Figure 8C-D) . These analyses suggest that G9a 291 inhibition may be effective in altering oncogenic gene expression programmes in MNA NB. 292
In order to further assess the alteration of oncogenic potential by G9a inhibition, we constructed 293 metagenes corresponding to BIX-01294 upregulated and downregulated genes. These metagenes act 294 as quantifiable model genes enabling the association with prognosis of grouped up/down regulated 295 genes. As shown in Figure 8E , high expression of BIX-01294 upregulated genes correlate with good 296 overall outcome, and low expression of these genes correlates with poor prognosis. Conversely, high 297 expression of BIX-01294 down-regulated genes correlates with poor overall outcome, and low 298 expression of these genes correlates with good prognosis. This strongly suggests that G9a represses 299 tumour suppressor genes in NB that can be reactivated by BIX-01294 treatment. The data also 300 suggests that G9a supports activation of genes associated with NB development, including MYCN 301 regulated genes. 302
Lastly, we validated some of the top genes identified after BIX-01294 treatment of LAN-1 cells in 303 two MNA (LAN-1 and Kelly) and two non-MNA NB (GI-M-EN and SK-N-AS) cell-lines treated 304 with UNC0638. As shown in Figure 8F , CLU, AMHR2, FLCN, and AKR1C1-3 were all upregulated 305 to varying extents following UNC0638 treatment, confirming good concordance between the actions 306 of BIX-01294 and UNC0638. We also confirmed down-regulation of the ALK oncogene, revealed by 307 our RNA sequencing, with UNC0638. The association between expression of individual genes and 308 clinical prognosis is summarized in Supplementary Table 2 , strongly suggesting that our BIX-309 01294/UNC0638 validated genes, AMHR2, FLCN, and AKR1C1-3 are amongst many novel NB 310 tumour suppressor genes found by our analysis. CLU, encoding clusterin, is already a known NB 2013). However, the effect and potential benefits of targeting G9a in NB remain unclear due to 322 limited analysis of the G9a protein in NB, activities and pathways regulated by G9a, and the absence 323 of assessment of second-generation inhibitors of G9a towards NB cells. In this study, we have 324 examined G9a expression in relation to NB disease stratifying factors, and also assessed three G9a 325 inhibitors. Based on our findings, as discussed below, we propose that pharmaceutical inhibition of 326
G9a is a viable therapeutic approach, especially for NB driven by MYCN amplification. 327
Our immunohistochemical analysis of G9a in NB shows for the first time that nuclear G9a is 328 markedly increased in poorly differentiated and undifferentiated NB, as also suggested by our mRNA 329 database mining and immunoblotting of thirteen NB cell-lines. Two other potentially critical G9a may also act similarly to PRMT5, which we have shown to directly methylate MYCN and 337 regulate its stability at the protein level (Park et al. 2015) . The need for further in-depth analyses to 338 explore the possible interplay of G9a and MYCN proteins is underlined by our expression data, as 339 well as functional and transcriptomic data (see below). 340
The correlation of G9a and EZH2 expression is also important when considering possible epigenetic 341 therapeutics for NB. Although G9a is mainly known to catalyse H3K9 dimethylation, it can also 342 methylate H3K27 (Tachibana et al. 2001 ) and it has been shown to be a key regulator of Polycomb 343
repressor Complex 2 (Mozzetta et al. 2014 ). In addition, it was shown in breast cancer cells that 344 effective gene re-expression necessitated the inhibition of both G9a and EZH2. For example, dual 345 depletion of G9a and EZH2 dramatically increased SPINK1 mRNA when individual depletion had no 346 effect. This dual inhibition was also shown to increase growth inhibition over only G9a or EZH2 single inhibition (Curry et al. 2015) . Given the increasing evidence for EZH2 involvement in NB, Our RNA sequencing following BIX-01294 treatment revealed upregulation of the established NB 371 tumour suppressors CLU, but also other putative tumour suppressors not previously associated with 372 NB. One example of this is the FLCN gene, encoding folliculin. Folliculin has been shown to 373 regulate AMP-activated kinase (AMPK), which enables regulation of cancer cell metabolism and 374 also autophagy (Possik et al. 2014; Yan et al. 2014 ). Notably, our upregulated genes also included 375 FNIP1 and FNIP2, encoding folliculin-interacting proteins 1 and 2, emphasising the potential 376 importance of this pathway in NB tumour suppression. Other putative tumour suppressor genes 377 include AMHR2, encoding Anti-Mullerian Hormone Receptor Type 2, also known as Mullerian Inhibiting Substance Type II Receptor. AMHR2 has been shown to suppress tumorigenicity in the 379 testes (Tanwar et al. 2012 ). The aldo keto-reductase 1 family genes (AKR1C1-3) encode 380 steroidogenic genes which, although expressed at high levels in some cancers (Zeng et al. 2017) , are 381 also downregulated in others such as breast and gastric cancers (Frycz et al. 2016; Wenners et al. 382 2016) . Of the down-regulated genes, several were histone genes, probably reflecting the decreased 383 G1 to S-phase progression in cells treated with inhibitors. The ALK gene was also decreased, 
